Skip to main content
SpringerLink
Log in

Genetic factors have a role in the development and treatment of eating disorders

  • Practical Issuses and Updates
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Grave RD. School-based prevention programs for eating disorders: achievements and opportunities. Dis Manage Health Outcomes 2003: 11(9): 579–93

    Article  Google Scholar 

  2. Gorwood P. Eating disorders, serotonin transporter polymorphisms and potential treatment response. Am J Pharmacogenomics 2004: 4(1): 9–17

    Article  PubMed  CAS  Google Scholar 

  3. Di Bella DD, Catalano M, Cavallini MC, et al. Serotonin transporter linked polymorphic region in anorexia nervosa and bulimia nervosa. Mol Psychiatry 2000 May; 5(3): 233–4

    Article  PubMed  Google Scholar 

  4. Ferguson CP, La Via MC, Crossan PJ, et al. Are serotonin selective reuptake inhibitors effective in underweight anorexia nervosa? Int J Eat Disord 1999 Jan; 25(1): 11–7

    Article  PubMed  CAS  Google Scholar 

  5. Mayer LE, Walsh BT. The use of selective serotonin reuptake inhibitors in eating disorders. J Clin Psychiatry 1998; 59Suppl. 15: 28–34

    PubMed  CAS  Google Scholar 

  6. Kaye WH, Weltzin TE, Hsu LK, et al. An open trial of fluoxetine in patients with anorexia nervosa. J Clin Psychiatry 1991 Nov; 52(11): 464–71

    PubMed  CAS  Google Scholar 

  7. Strober M, Freeman R, DeAntonio M, et al. Does adjunctive fluoxetine influence the post-hospital course of restrictor-type anorexia nervosa? A 24-month prospective, longitudinal follow-up and comparison with historical controls. Psychopharmacol Bull 1997; 33(3): 425–31

    PubMed  CAS  Google Scholar 

  8. Kaye WH, Nagata T, Weltzin TE, et al. Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol Psychiatry 2001 Apr 1; 49(7): 644–52

    Article  PubMed  CAS  Google Scholar 

  9. Ricca V, Mannucci E, Mezzani B, et al. Fluoxetine and fluvox-amine combined with individual cognitive-behaviour therapy in binge eating disorder: a one-year follow-up study. Psychother Psychosom 2001 Nov–Dec; 70(6): 298–306

    Article  PubMed  CAS  Google Scholar 

  10. Romano SJ, Halmi KA, Sarkar NP, et al. A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment. Am J Psychiatry 2002 Jan; 159(1): 96–102

    Article  PubMed  Google Scholar 

  11. Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev 2001; (4): CD003391

    PubMed  Google Scholar 

  12. Hudson JI, McElroy SL, Raymond NC, et al. Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial. Am J Psychiatry 1998 Dec; 155(12): 1756–62

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Genetic factors have a role in the development and treatment of eating disorders. Drugs Ther. Perspect 21, 23–25 (2005). https://doi.org/10.2165/00042310-200521040-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200521040-00008

Search

Navigation